Compare TMDE & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TMDE | ALLR |
|---|---|---|
| Founded | 2016 | 2004 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2M | 19.3M |
| IPO Year | N/A | 2021 |
| Metric | TMDE | ALLR |
|---|---|---|
| Price | $0.80 | $1.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | ★ 285.6K | 204.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.61 |
| 52 Week High | $2.75 | $2.35 |
| Indicator | TMDE | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 58.15 | 48.32 |
| Support Level | $0.81 | $0.80 |
| Resistance Level | $1.02 | $0.96 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 67.32 | 55.17 |
TMD Energy Ltd is engaged in marine fuel bunkering services specializing in the supply and marketing of marine gas oil and marine fuel oil (including high sulfur fuel oil, low sulfur fuel oil and very low sulfur fuel oil), to ships and vessels at sea. It is also involved in the provision of ship management services for in-house and external vessels, as well as vessel chartering. It is currently operating with a fleet of nearly 15 bunkering vessels ranging from 540 dwt to 7,820 dwt, of which nearly nine (9) are double bottom and double hull vessels with an average cargo-carrying capacity of approximately 4,200 dwt each.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.